CRYO CELL INTERNATIONAL Business Summary

Cryo-Cell International Inc. (CCEL) operates a high-margin, vertically integrated business model centered on the collection, processing, and long-term cryogenic storage of umbilical cord blood and tissue stem cells. The company generates revenue through a combination of upfront processing and testing fees and recurring annual storage subscriptions, which provide a stable, long-term cash flow profile. Its operations are divided into three primary segments: private cellular processing and storage for family use, public cord blood banking (expanded via the acquisition of CORD:USE), and the manufacturing of the proprietary PrepaCyte CB processing system. As the world’s first private cord blood bank, Cryo-Cell has evolved from a pure-play storage provider into a regenerative medicine leader, leveraging an exclusive license agreement with Duke University to develop clinical infusion treatments for neurological conditions. In the competitive landscape, Cryo-Cell maintains a premium market position against direct rivals such as Cord Blood Registry (CBR), Viacord (a Revvity company), Americord, and AlphaCord, distinguishing itself through FACT accreditation and its unique transition into clinical cellular therapy. Originally founded in 1989 by Dan Richard, the company’s current strategic direction is steered by Co-CEOs David I. Portnoy and Mark L. Portnoy, who assumed leadership in 2011 following a successful proxy contest. David Portnoy, a Wharton alumnus with a background in venture capital and fixed-income trading, serves as Chairman and a major stakeholder, while Mark Portnoy oversees core business expansion and technology adoption. The executive team is supported by long-tenured CFO Jill Taymans, who has been with the firm since 1998, and Chief Information Officer Oleg Mikulinsky, a serial software entrepreneur. A critical pillar of the company’s scientific pedigree is Medical Director Dr. Joanne Kurtzberg, an internationally renowned pioneer who performed the first unrelated cord blood transplant and leads the Marcus Center for Cellular Cures at Duke. Notable institutional backing includes significant positions held by Hamilton Lane Incorporated and The Vanguard Group, alongside a board featuring seasoned professionals like Harold D. Berger and Daniel Mizrahi.